Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBIL1TY NSCLC-06: Acasunlimab + pembrolizumab vs docetaxel in PD-L1 positive metastatic NSCLC after prior PD-1/PD-L1 and platinum chemotherapy
jRCT2051240178Phase 3Active, not recruiting
- Sponsor
- Genmab
- Start
- Jan 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Acasunlimab + pembrolizumab (Q6W) with Docetaxel (Q3W) (2 arms). Primary endpoint: Overall survival. Started Jan 2025; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240178.